Cancer research has long relied on traditional two-dimensional cell cultures and animal models to study tumor biology and test potential therapies. While these systems have contributed valuable insights, they often fail to capture the complex three-dimensional architecture, cellular heterogeneity, and dynamic microenvironment of human tumors. This gap between preclinical models and clinical reality is a major contributor to the high failure rate of oncology drugs in clinical trials. Recent advances in additive manufacturing, particularly three-dimensional (3D) bioprinting, are offering a transformative path forward. Among the most promising developments are 3D bioprinted vascularized tumor models—engineered constructs that replicate not only the solid tumor mass but also its supporting blood vessel network. By more faithfully mimicking the in vivo tumor microenvironment, these models hold the potential to accelerate drug discovery, enable personalized treatment strategies, and reduce reliance on animal testing.

What Are 3D Bioprinted Vascularized Tumor Models?

A 3D bioprinted vascularized tumor model is a laboratory-constructed tissue that combines malignant cells, extracellular matrix (ECM) components, and a perfusable vascular network within a single three-dimensional scaffold. The process begins with bioinks—formulations that contain living cells (such as cancer cell lines or patient-derived tumor cells), hydrogels (e.g., gelatin, alginate, collagen, or fibrin), and sometimes growth factors or other bioactive molecules. Using extrusion-based, inkjet, laser-assisted, or stereolithographic bioprinting techniques, these bioinks are deposited layer by layer to form a construct that mimics the spatial organization of a real tumor.

The key differentiator of vascularized tumor models is the intentional incorporation of endothelial cells (typically human umbilical vein endothelial cells or induced pluripotent stem cell derived endothelial cells) to create a lining for microchannels that simulate blood vessels. Some approaches also include perivascular cells (pericytes) and smooth muscle cells to enhance vessel stability. After printing, the construct may be cultured in a perfusion bioreactor that delivers nutrients and oxygen through these channels, sustaining the viability of the embedded tumor cells over extended periods. This circulatory system is not a mere cosmetic addition; it is essential for studying how nutrients, oxygen, and therapeutic agents penetrate the tumor mass—a process that profoundly influences tumor growth and drug response.

The Critical Role of Vascularization in Tumor Biology

In solid tumors, angiogenesis—the formation of new blood vessels from existing vasculature—is a hallmark of cancer progression. Tumors rapidly outgrow the diffusion limits of oxygen and nutrients (typically 100–200 micrometers), triggering a hypoxic response that upregulates pro‑angiogenic factors such as vascular endothelial growth factor (VEGF). The resulting vessel network is often leaky, tortuous, and heterogeneous, creating regions of high interstitial fluid pressure and poor drug delivery. This abnormal vasculature directly contributes to therapy resistance and metastasis.

Conventional 3D cancer models (e.g., spheroids or organoids grown without a vascular network) cannot replicate these critical fluidic and mechanical features. Drugs that appear effective in an avascular spheroid may fail to penetrate a vascularized tumor, or may be pumped out by the dysfunctional vessels. By embedding functional vasculature from the outset, bioprinted models enable researchers to study phenomena such as vascular permeability, interstitial flow, and tumor‑endothelial cell crosstalk in a controlled yet realistic setting. For example, scientists can monitor how chemotherapeutic agents extravasate from the vessel lumen into the tumor interstitium, or how immune cells are recruited across the endothelium—processes that are difficult to observe in either 2D cultures or static 3D constructs.

Advantages of Vascularized Tumor Models

Enhanced Realism and Microenvironment Recapitulation

The most immediate benefit of vascularized tumor models is their structural and functional fidelity. By recreating the three-dimensional arrangement of cancer cells, stromal cells, ECM, and blood vessels, these models more accurately reflect the biophysical and biochemical cues that govern tumor behavior. The presence of perfusable channels allows researchers to establish oxygen and nutrient gradients similar to those seen in vivo, leading to more physiologically relevant zones of proliferation, quiescence, and necrosis. This level of realism is impossible to achieve with conventional 2D monolayers or even standard 3D spheroids. As a result, studies of cell signaling, gene expression, and metabolism yield data that better predict clinical outcomes.

Improved Drug Testing and Screening

One of the primary drivers for developing vascularized tumor models is the need for better preclinical drug testing platforms. Current 2D‑based high‑throughput screening frequently generates false positives or negatives because it fails to account for the barriers that drugs encounter in a vascularized tumor. Bioprinted vascularized models enable more accurate assessment of drug penetration, distribution, and efficacy. For instance, researchers can introduce a fluorescently labeled anticancer compound into the perfusing medium and quantify how deeply it penetrates the tumor mass over time. They can also measure the impact of the drug on endothelial integrity, which may affect subsequent dosing. Several studies have shown that the half‑maximal inhibitory concentration (IC₅₀) values obtained from vascularized models correlate more closely with clinical responses than those from monoculture spheroids. This improved predictivity could significantly reduce the attrition rate of drug candidates in clinical trials, saving time and resources.

Personalized Medicine and Patient‑Specific Models

An exciting frontier is the use of patient‑derived cells to create personalized vascularized tumor models. Bioprinting can incorporate a patient’s own tumor cells (obtained from a biopsy or surgical resection) along with autologous endothelial cells or induced pluripotent stem cell‑derived vascular components. These constructs can be used to test the sensitivity of an individual’s tumor to various chemotherapeutic agents, targeted therapies, or immunotherapies before treatment begins. Early proof‑of‑concept studies have demonstrated that vascularized models derived from patient‑specific glioblastoma or breast cancer tissues recapitulate key molecular features of the original tumor, including mutational profiles and drug resistance mechanisms. Such platforms could eventually guide oncologists in selecting the most effective therapy for each patient, reducing trial‑and‑error prescribing and improving outcomes.

Ethical and Practical Benefits

Beyond scientific advantages, vascularized tumor models support the 3Rs principle (Replacement, Reduction, Refinement) in animal research. While animal models remain indispensable for certain types of studies (e.g., whole‑body pharmacokinetics, immune system interactions), many mechanistic and screening experiments can be effectively performed in bioprinted constructs. This reduces the number of animals required and the associated ethical concerns. Furthermore, these models can be produced with a high degree of reproducibility and scalability, making them suitable for industrial screening workflows. They also enable continuous monitoring using live‑cell imaging, biosensors, and microfluidic sampling—capabilities that are difficult to achieve in live animals.

Current Challenges and Technical Hurdles

Ensuring Stability of Vascular Networks

Despite rapid progress, constructing stable, functional vascular networks within a tumor model remains a significant challenge. The newly formed microchannels must be perfused without causing shear stress that damages the cell lining, and they must maintain patency over days to weeks to support long‑term experiments. Leaking vessels, thrombosis, and network remodeling (e.g., sprouting or regression) can compromise the model’s utility. Researchers are exploring various strategies to improve vascular stability, including co‑culture with mural cells (pericytes, smooth muscle cells), optimization of hydrogel stiffness and porosity, and addition of angiogenic factors in a spatiotemporal manner. Some groups are also developing sacrificial materials—such as gelatin or Pluronic F127—that can be printed as a template for channel formation and then removed to leave hollow conduits that are later endothelialized.

Replicating Tumor Microenvironment Complexity

The tumor microenvironment (TME) is not merely a collection of cancer cells and blood vessels. It includes a diverse array of immune cells (T cells, macrophages, neutrophils), fibroblasts (cancer‑associated fibroblasts), adipocytes, and specialized ECM components. The TME also exhibits gradients of oxygen, pH, and metabolites, as well as mechanical forces from interstitial flow and matrix stiffness. Most current bioprinted models simplify this complexity by using only a few cell types. Incorporating the full spectrum of stromal and immune cells—while maintaining their viability and phenotype—poses a major biofabrication challenge. Moreover, the immune system’s role in tumor progression and therapy response is highly dynamic; capturing that dynamism in a model may require the integration of microfluidic devices that allow for recirculation of immune cells and cytokines.

Integration of Immune Cells and Stroma

A particularly active area of research is the incorporation of immune cells into vascularized tumor models. Because many immunotherapies (e.g., checkpoint inhibitors, CAR‑T cells) rely on the interaction between immune cells and the tumor vasculature, models lacking a functional immune component cannot fully predict therapeutic responses. Several groups have begun to embed T cells, macrophages, or dendritic cells within the ECM or circulating in the perfusate. However, maintaining the activation state and motility of these cells over extended periods is nontrivial. The printed hydrogel must be permissive enough for immune cell migration yet stiff enough to support the overall architecture. Additionally, the presence of endothelial cells can modulate immune cell behavior through adhesion molecules and chemokine gradients, adding another layer of complexity that must be carefully controlled.

Standardization and Reproducibility

For bioprinted tumor models to be widely adopted in industrial and clinical settings, they must be produced with consistent quality across batches and laboratories. Currently, there is a lack of standardized protocols for bioink composition, printing parameters, and post‑printing culture conditions. The choice of cancer cell line, endothelial cell source, and hydrogel can dramatically affect the model’s behavior. Efforts such as the development of common reference materials, sharing of open‑source design files, and establishment of community guidelines are underway but still in their infancy. Regulatory acceptance of these models as alternatives to animal testing will also require robust validation against historical data from animal and human studies.

Recent Advances and Breakthroughs

Despite these obstacles, the field has witnessed remarkable achievements in the past few years. In 2021, a team from the University of Pennsylvania Lung Cancer Research Center reported the fabrication of a vascularized non‑small cell lung cancer model using a coaxial extrusion bioprinting system. They printed a core‑shell structure with a hydrogel‑based cancer cell core and an endothelialized shell, and used microfluidic perfusion to maintain viability for over two weeks. More recently, researchers at the Swiss Federal Institute of Technology (EPFL) developed a 3D bioprinted glioblastoma model that included not only tumor cells and vasculature but also astrocytes and microglia. By incorporating patient‑derived cells, they were able to recapitulate the invasive behavior of glioblastoma along blood vessels—a phenomenon known as perivascular invasion that is a hallmark of the disease.

Another notable advance comes from the field of liver cancer. A group at Tsinghua University printed a vascularized hepatocellular carcinoma model and demonstrated that it exhibited more clinically relevant responses to sorafenib than conventional spheroids, including the occurrence of drug‑induced hypertension (a common side effect mediated by endothelial damage). These studies underscore the potential of vascularized models to capture not only efficacy but also toxicity endpoints.

Future Directions and Clinical Translation

Going forward, several key developments are expected to propel vascularized tumor models from research tools to mainstream platforms. First, the integration of organ‑on‑a‑chip technology with bioprinting will allow for even greater control over fluid flow, mechanical cues, and multi‑organ interactions. For instance, a “tumor‑on‑a‑chip” system could be linked to a liver‑on‑a‑chip to study drug metabolism and hepatotoxicity simultaneously. Second, advances in bioprinting resolution—driven by two‑photon polymerization and micro‑scale continuous printing—will enable the construction of capillary‑level networks, bringing the models closer to the native microcirculation.

Third, the incorporation of real‑time sensing and feedback mechanisms will transform these models into smart platforms that can report on tumor progression and treatment response in situ. Embedding micro‑electrodes for impedance sensing or using fluorescent reporters for key signaling pathways are already being explored. Fourth, the push toward personalized medicine will drive the development of “biopsy‑to‑bioprint” workflows that can generate a patient‑specific vascularized model within days, enabling rapid therapy selection. This will require automation of the entire pipeline—from cell isolation and expansion to printing, perfusion, and analysis.

Finally, regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are beginning to recognize the value of advanced in vitro models. The FDA’s Modernization Act 2.0, passed in 2022, encourages the use of alternatives to animal testing where appropriate. As vascularized tumor models become standardized and validated, they could become a cornerstone of preclinical oncology research, potentially reducing animal use by 30–50% in certain areas.

Conclusion

3D bioprinted vascularized tumor models represent a significant advance in cancer research, bridging the gap between overly simplistic in vitro systems and complex, ethically fraught animal experiments. By replicating the tumor’s three‑dimensional structure, supporting blood vessel network, and dynamic microenvironment, these models offer unprecedented opportunities to study cancer biology, test drug candidates, and tailor therapies to individual patients. While challenges remain—particularly in maintaining vascular stability, incorporating immune cells, and achieving standardization—the pace of innovation is accelerating. As bioprinting technologies mature and interdisciplinary collaborations deepen, these engineered tumor models are poised to transform preclinical oncology, ultimately contributing to more efficient drug development and better outcomes for patients. The journey from bench to bedside is long, but with each printed vessel and perfused channel, the path becomes clearer.